Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[<i>c</i>][1,2,5]oxadiazole Derivatives as Potent PD-L1 Inhibitors with <i>In Vivo</i> Antitumor Activity
作者:Liu Liu、Zhiying Yao、Shijun Wang、Tao Xie、Guoqing Wu、Honghan Zhang、Pu Zhang、Yaojun Wu、Haoliang Yuan、Hongbin Sun
DOI:10.1021/acs.jmedchem.1c00392
日期:2021.6.24
A series of novel benzo[c][1,2,5]oxadiazole derivatives were designed, synthesized, and biologically evaluated as inhibitors of PD-L1. Among them, compound L7 exhibited 1.8 nM IC50 value in a homogeneous time-resolved fluorescence (HTRF) assay, which was 20-fold more potent than the lead compound BMS-1016. In the surface plasmon resonance (SPR) assay, L7 bound to human PD-L1 (hPD-L1) with a KD value
设计、合成了一系列新型苯并[ c ][1,2,5]恶二唑衍生物,并对其作为PD-L1抑制剂进行了生物学评价。其中,化合物L7在均相时间分辨荧光(HTRF)测定中表现出1.8 nM IC 50值,其效力比先导化合物BMS-1016强20倍。在表面等离子共振 (SPR) 测定中, L7与人 PD-L1 (hPD-L1) 结合, KD值为3.34 nM,但未显示与 hPD-1 的任何结合。在基于细胞的共培养测定中, L7阻断 PD-1/PD-L1 相互作用,EC 50值为 375 nM,而BMS-1016的 EC 50值为 2075 nM。此外,化合物L24 ( L7的酯前药)具有口服生物利用度,并且在同基因小鼠和PD-L1人源化小鼠的肿瘤模型中显示出显着的抗肿瘤作用。从机制上讲, L24可能通过促进抗肿瘤免疫而表现出显着的体内抗肿瘤作用。总之,这一系列苯并恶二唑 PD-L1 抑制剂为肿瘤免疫治